BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...

I want to express my gratitude to Sen. Bob Casey for his steadfast dedication to the fight against Alzheimer’s disease during ...

Middlemen negotiate prescription costs at thousands of different price points, depending on your insurance plan.